Αναζήτηση Δραστικών

SAQUINAVIR

ATC

Εμπορικές Ονομασίες

  • DRUGBANK - Saquinavir
  • indication:

    For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.

  • pharmacology:

  • mechanism:

    Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

  • toxicity:

    Probably experience pain in the throat

  • absorprion:

    Absolute bioavailability averages 4%

  • halflife:

  • roouteelimination:

    In vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Only 1% of saquinavir is excreted in the urine, so the impact of renal impairment on saquinavir elimination should be minimal.

  • volumedistribution:

    * 700 L

  • clearance:

    * 1.14 L/h/kg [Healthy volunteers receiving IV doses of 6, 36, and 72 mg]